Calculus Capital invests £2.1m in capital’s Synpromics

Private equity fund manager Calculus Capital has invested £2.1 million in Edinburgh-based synthetic biology firm Synpromics.

Synpromics is a privately-backed synthetic biology business with “unique IP and know-how” in the development and application of synthetic promoters.

Promoters control the expression of proteins and Synpromics’ technology allows it to develop custom made solutions in all areas of gene expression.

Calculus said synthetic promoters represent a “powerful new technology” for improvements in product targeting in areas such as gene and cell therapy.

In a statement, Calculus also said Synpromics has shown that it can achieve significant yield improvements in bioprocessing.

The funds injection will be used for business expansion and further development of Synpromics’ proprietary synthetic promoter technology.

Alexandra Lindsay, investment director at Calculus said: “We are very excited to invest in Synpromics. The highly capable team, comprehensive IP and leading technology, together with Calculus Capital’s support, will ensure Synpromics is primed to take full advantage of the significant market opportunity available.”